CO5130022A1 - Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial - Google Patents

Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial

Info

Publication number
CO5130022A1
CO5130022A1 CO99058020A CO99058020A CO5130022A1 CO 5130022 A1 CO5130022 A1 CO 5130022A1 CO 99058020 A CO99058020 A CO 99058020A CO 99058020 A CO99058020 A CO 99058020A CO 5130022 A1 CO5130022 A1 CO 5130022A1
Authority
CO
Colombia
Prior art keywords
drug
agent
oralally
administered
optionally
Prior art date
Application number
CO99058020A
Other languages
English (en)
Inventor
Talwar Naresh
Sen Himadri
John N Staniforth
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/152,932 external-priority patent/US6261601B1/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of CO5130022A1 publication Critical patent/CO5130022A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una composición farmacéutica en forma de tabletas o cápsulas provee una combinación de control temporal y espacial de la liberación de una droga a un paciente para resultados terapéuticos efectivos. La composición farmacéutica comprende una droga, un componente generador de gas, un agente dilatador, un agente viscoso, y opcionalmente un polímero formador de gel. El agente dilatador pertenece a un grupo de compuestos conocidos como superdesintegradores (por ejemplo: la polivinilpirrolidona de enlace cruzado o la carboximetilcelulosa de sodio). Inicialmente el agente viscoso y luego el polímero formador de gel, forman una matriz de gel hidratada que ocluye el gas, causando que la tableta o cápsula floten para ser retenidas en el estomago o en la parte alta del intestino delgado (control espacial). Al mismo tiempo la matriz de gel hidratado crea un camino de difusión tortuoso para la droga, lo que resulta en una liberación sostenida de la droga (control temporal). Una formulación, preferida, de ciprofloxacin administrada una sola vez al día comprende 69.9% de base de ciprofloxacin, 0.34% de alginato de sodio, 1.03% de goma jantica, 13.7% de bicarbonato de sodio, 12.1% de polivinilpirrolidona de enlace cruzado, y opcionalmente otros excipientes farmacéuticos la formulación esta en forma de tabletas recubiertas o no, o en cápsulas.
CO99058020A 1998-09-14 1999-09-14 Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial CO5130022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/152,932 US6261601B1 (en) 1997-09-19 1998-09-14 Orally administered controlled drug delivery system providing temporal and spatial control

Publications (1)

Publication Number Publication Date
CO5130022A1 true CO5130022A1 (es) 2002-02-27

Family

ID=22545063

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99058020A CO5130022A1 (es) 1998-09-14 1999-09-14 Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial

Country Status (41)

Country Link
EP (2) EP1281397A1 (es)
JP (1) JP2002524494A (es)
CN (1) CN1186013C (es)
AP (1) AP1659A (es)
AR (1) AR022672A1 (es)
AT (1) ATE245414T1 (es)
AU (1) AU758324B2 (es)
BG (1) BG105339A (es)
BR (1) BR9913696A (es)
CA (1) CA2343760A1 (es)
CO (1) CO5130022A1 (es)
CU (1) CU23040A3 (es)
CZ (1) CZ2001901A3 (es)
DE (1) DE69909801T2 (es)
DK (1) DK1107741T3 (es)
EA (2) EA004443B1 (es)
EE (1) EE200100153A (es)
ES (1) ES2204098T3 (es)
GE (1) GEP20043216B (es)
HK (1) HK1037967A1 (es)
HR (1) HRP20010187B1 (es)
HU (1) HUP0103632A3 (es)
ID (1) ID29843A (es)
IL (1) IL141977A0 (es)
IS (1) IS5885A (es)
MX (1) MXPA01002634A (es)
MY (1) MY127952A (es)
NO (1) NO20011276L (es)
NZ (2) NZ510487A (es)
OA (1) OA11652A (es)
PE (1) PE20001058A1 (es)
PL (1) PL346798A1 (es)
PT (1) PT1107741E (es)
SI (1) SI1107741T1 (es)
SK (1) SK285478B6 (es)
SV (1) SV1999000152A (es)
TR (1) TR200100731T2 (es)
UA (1) UA73287C2 (es)
UY (1) UY25710A1 (es)
WO (1) WO2000015198A1 (es)
ZA (1) ZA995839B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263409A1 (en) * 2000-03-03 2002-12-11 Ranbaxy Laboratories, Limited Orally administered controlled delivery system for once daily administration of ciprofloxacin
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
AU2006202275A1 (en) * 2000-06-26 2006-06-22 Bayer Healthcare Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
AR030128A1 (es) * 2000-08-08 2003-08-13 Daiichi Seiyaku Co Una preparacion solida altamente absorbible
IN192748B (es) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
JP2004513975A (ja) * 2000-12-05 2004-05-13 マクグレゴール アレキサンダー 作用物質の制御放出のための静水圧デリバリシステム
ATE477795T1 (de) 2001-07-04 2010-09-15 Sun Pharma Advanced Res Co Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
CN1543337A (zh) * 2001-08-16 2004-11-03 ���ո����ɸߵȽ�����ίԱ�������� 可膨胀的胃潴留装置
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
AU2002351798A1 (en) * 2001-10-29 2003-05-12 Labopharm Inc. Methods and dosage forms for improving the bioavailability of therapeutic agents
RU2322263C2 (ru) * 2001-11-13 2008-04-20 Астеллас Фарма, Инк. Система продолжительного высвобождения растворимого лекарственного средства
ES2259011T3 (es) 2001-11-19 2006-09-16 Lupin Limited Composicion farmaceutica para la liberacion controlada de un antibiotico beta-lactama.
HUP0500217A2 (hu) * 2002-04-23 2005-06-28 Lupin Limited Tartós hatású, módosított hatóanyag-leadású mátrix készítmények
WO2005018613A1 (de) * 2003-08-26 2005-03-03 Mandapro Ag Pellets für die orale applikation von pharmazeutischen wirkstoffen
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
GB0501810D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Chemotherapeutic formulations
AU2006263338A1 (en) * 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
WO2010020098A1 (zh) 2008-08-18 2010-02-25 北京天衡药物研究院 胃滞留药物释出系统及其制备方法和用途
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
TWI705814B (zh) * 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
EP3220894B1 (en) * 2014-11-19 2021-03-10 DuPont Nutrition USA, Inc. Nanosuspension formulation
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
DK3648747T3 (da) 2017-06-16 2022-11-28 Amneal Complex Products Res Llc Gastroretentive doseringsformer til vedvarende frigivelse af lægemidler
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
EP4056172A1 (en) 2018-06-18 2022-09-14 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
ES2901522T3 (es) 2018-06-27 2022-03-22 Amneal Complex Products Res Llc Sistemas de suministro de fármacos gastrorretentivos osmóticos autorregulados
CN110448535A (zh) * 2019-09-04 2019-11-15 湖南宇山玉月农业科技有限公司 一种裂褶菌素胃漂浮片
CN111116794A (zh) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 一种中性造纸用聚合材料的制备方法
CN115715765A (zh) * 2021-08-24 2023-02-28 江苏万邦生化医药集团有限责任公司 一种悬浮片剂
CN113768898A (zh) * 2021-09-14 2021-12-10 江苏万邦生化医药集团有限责任公司 悬浮的胶囊片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤

Also Published As

Publication number Publication date
EA005767B1 (ru) 2005-06-30
ZA995839B (en) 2000-03-28
EA200100346A1 (ru) 2001-10-22
BG105339A (en) 2001-11-30
AU1779499A (en) 2000-04-03
GEP20043216B (en) 2004-04-26
MY127952A (en) 2007-01-31
AR022672A1 (es) 2002-09-04
CN1325299A (zh) 2001-12-05
EP1107741A1 (en) 2001-06-20
SV1999000152A (es) 2000-07-03
AP1659A (en) 2006-09-06
HK1037967A1 (en) 2002-03-01
PL346798A1 (en) 2002-02-25
HUP0103632A2 (hu) 2002-02-28
ID29843A (id) 2001-10-18
IS5885A (is) 2001-03-12
DE69909801D1 (de) 2003-08-28
PE20001058A1 (es) 2000-10-05
HUP0103632A3 (en) 2005-06-28
SK3472001A3 (en) 2001-10-08
EP1107741B1 (en) 2003-07-23
SI1107741T1 (en) 2004-02-29
HRP20010187B1 (en) 2004-04-30
NO20011276D0 (no) 2001-03-13
UY25710A1 (es) 2000-03-31
AU758324B2 (en) 2003-03-20
TR200100731T2 (tr) 2001-06-21
AP2001002098A0 (en) 2001-03-31
EP1281397A1 (en) 2003-02-05
CZ2001901A3 (cs) 2001-08-15
JP2002524494A (ja) 2002-08-06
IL141977A0 (en) 2002-03-10
HRP20010187A2 (en) 2002-04-30
SK285478B6 (sk) 2007-02-01
PT1107741E (pt) 2003-12-31
BR9913696A (pt) 2001-10-09
ES2204098T3 (es) 2004-04-16
MXPA01002634A (es) 2002-06-04
EA004443B1 (ru) 2004-04-29
WO2000015198A1 (en) 2000-03-23
CA2343760A1 (en) 2000-03-23
EA200300847A1 (ru) 2003-12-25
CU23040A3 (es) 2005-04-14
NZ523747A (en) 2004-04-30
NO20011276L (no) 2001-05-10
NZ510487A (en) 2003-04-29
ATE245414T1 (de) 2003-08-15
DK1107741T3 (da) 2003-11-17
EE200100153A (et) 2002-06-17
UA73287C2 (en) 2005-07-15
CN1186013C (zh) 2005-01-26
OA11652A (en) 2004-12-08
DE69909801T2 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
CO5130022A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
YU19501A (sh) Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
AU7465087A (en) Controlled release bioerodible drug delivery system
KR20010102088A (ko) 질에 투여되는 연장방출 생물접착성 겔약형
DE60117801D1 (de) Pharmazeutische zusammensetzung mit gesteuerter freigabe und verzögerter absorption
DE60038536D1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
SG146638A1 (en) Pharmaceutical delivery system
JP2001510795A5 (es)
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
SE9301877D0 (sv) In situ gel for therapeutic use
ECSP993138A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
HRP20020258B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
EP4217001A1 (en) Composition and method for prevention and treatment of cutaneous radiation injury
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
HRP20050448A2 (en) Extended, controlled release pharmaceutical composition comprising charged polymers
TH50543A3 (th) ระบบการนำส่งยาที่ควบคุมได้สำหรับให้ทางปากซึ่งให้การควบคุมเกี่ยวกับเวลาและบริเวณ
CO5011086A1 (es) Budesonida sola o en combinacion con acido ursodesoxicolico en la terapia de enfermedades colestasicas del higado
AR043470A2 (es) Una composicion farmaceutica para ser usada como anticonceptivo
AR029327A1 (es) Uso de la levobupivacaina para la preparacion de medicamentos de aplicacion en el anestesiamiento de pacientes sujetos a intervencion de cirugia mayor